A phase-1b study of everolimus plus paclitaxel in patients with small-cell lung cancer. - Wikidata - wikimedia - TriplyDB

A phase-1b study of everolimus plus paclitaxel in patients with small-cell lung cancer.

A phase-1b study of everolimus plus paclitaxel in patients with small-cell lung cancer.

http://www.wikidata.org/entity/Q33409908

about

Targeted drugs in small-cell lung cancer Addition of rapamycin and hydroxychloroquine to metronomic chemotherapy as a second line treatment results in high salvage rates for refractory metastatic solid tumors: a pilot safety and effectiveness analysis in a small patient cohort SPAG5 upregulation predicts poor prognosis in cervical cancer patients and alters sensitivity to taxol treatment via the mTOR signaling pathway.A Translational, Pharmacodynamic, and Pharmacokinetic Phase IB Clinical Study of Everolimus in Resectable Non-Small Cell Lung Cancer Control of the MYC-eIF4E axis plus mTOR inhibitor treatment in small cell lung cancer.Current clinical regulation of PI3K/PTEN/Akt/mTOR signalling in treatment of human cancer.Fisetin Enhances Chemotherapeutic Effect of Cabazitaxel against Human Prostate Cancer Cells.Combined treatment strategies for microtubule stabilizing agent-resistant tumors.[Advances of molecular targeted therapy in squamous cell lung cancer].

P2860

Q26767017-C790EA32-2557-4632-A014-E462EC084C57 Q33422577-03E230C5-9D63-4636-8907-B8F8FCDF877C Q33720115-97948C7C-AB88-4B7F-B568-612F1F61ADDC Q35463464-1A728387-B627-427A-8D36-3DAAAE5D3437 Q35605425-217C0C1D-EEDD-41D5-AF0C-7384CBF607D6 Q38242086-0FEFE57A-747E-47A8-97AB-9F8DD6495413 Q38739235-01C611FC-85A0-45AF-A500-AA77C0BCED5D Q38908225-65C0FAB1-6175-4DA0-AC65-685FA1DBC96E Q53077916-7A51C01E-E703-4354-A21B-8BBFC4243710

P2860

A phase-1b study of everolimus plus paclitaxel in patients with small-cell lung cancer.

http://www.wikidata.org/entity/Q33409908

description

2013 nî lūn-bûn

@nan

2013 թուականի Օգոստոսին հրատարակուած գիտական յօդուած

@hyw

2013 թվականի օգոստոսին հրատարակված գիտական հոդված

@hy

2013年の論文

@ja

2013年論文

@yue

2013年論文

@zh-hant

2013年論文

@zh-hk

2013年論文

@zh-mo

2013年論文

@zh-tw

2013年论文

@wuu

name

A phase-1b study of everolimus plus paclitaxel in patients with small-cell lung cancer.

@ast

A phase-1b study of everolimus plus paclitaxel in patients with small-cell lung cancer.

@en

type

label

A phase-1b study of everolimus plus paclitaxel in patients with small-cell lung cancer.

@ast

A phase-1b study of everolimus plus paclitaxel in patients with small-cell lung cancer.

@en

prefLabel

A phase-1b study of everolimus plus paclitaxel in patients with small-cell lung cancer.

@ast

A phase-1b study of everolimus plus paclitaxel in patients with small-cell lung cancer.

@en

P1433

Q33409908-BB27E273-037C-4992-A028-85C5E52421E7

P1476

Q33409908-7408BEA6-1FCA-4422-914E-153CE69148EB

P2093

Q33409908-0D8840CC-216A-469E-A460-D5EF0D92C3B8

Q33409908-0F142C1B-1257-471B-9327-9B4E61B5F93D

Q33409908-1818C01C-7208-476E-9780-7E2D8DFE81CA

Q33409908-66D0F5ED-5316-4636-BBA7-989232F52AC1

Q33409908-6D473E3B-83E2-475B-AA55-3A27858FDB5D

Q33409908-BD00B028-8E9A-4428-9DC9-C12E501C0DD6

Q33409908-C63ACD55-AD9C-4E9B-BB5B-7C58CB68292D

Q33409908-C87D6277-2FF0-4C17-BD67-9A8F74502242

Q33409908-CFD2009D-F323-4A8B-BC48-479C3904AA11

P2860

Q33409908-19EFC201-0BE0-4BCF-83C5-090DBAA473D8

Q33409908-29859978-E116-4230-9758-401506BDF993

Q33409908-30BFDC04-1902-4B2C-96EE-B7B8E5F52EDF

Q33409908-3886FE6D-0557-4B97-928D-CA8F5DA4E930

Q33409908-4054B9DE-11B7-421E-A5DF-EDE89D88B46B

Q33409908-4545A7EC-109D-41BE-A955-9B7FDE48504E

Q33409908-49AE3A7D-D58F-4FF7-8089-D0F4ADEA7F24

Q33409908-73B2A403-7FF7-4D4B-BF03-80D09CFA0711

Q33409908-76AEDDF0-0C59-4D30-8765-A994F2C56228

Q33409908-7A0D80B6-452C-4970-ADDC-7ACCF24443D2

P2888

Q33409908-E10DF8F2-098C-46C6-9DE4-E4D976526DF0

P304

Q33409908-359C5236-6BB0-4B3B-9F55-BEEF2957A883

P31

Q33409908-C418C673-796B-40CE-AEDE-A5D6BCF97288

P356

Q33409908-3E923E89-8460-4B4C-88BA-57D0A5BC52F0

P407

Q33409908-F9D01173-C227-455F-A906-172311F322E4

P433

Q33409908-56ED294D-EA2B-4589-9604-E4CE4F4A8AB4

P478

Q33409908-31F241C1-1423-4104-AD05-8AF0094C6AD4

P577

Q33409908-EFDD8971-A2B2-4EB8-9FE6-65CFB2E41514

P5875

Q33409908-01D3871B-2FBD-4A77-B371-20344075A9B6

P6179

Q33409908-5CBE9202-6C83-42FF-ABDA-7E9652785E0F

P698

Q33409908-38CB3F3A-4748-4F0E-9D7C-183113DB0F2A

P932

Q33409908-88104AB4-225C-4AA1-8576-6A631AE08066

P356

P1433

British Journal of Cancer

P1476

A phase-1b study of everolimus plus paclitaxel in patients with small-cell lung cancer.

@en

P2093

I G Do

http://www.w3.org/2001/XMLSchema#string

J Lee

http://www.w3.org/2001/XMLSchema#string

J M Sun

http://www.w3.org/2001/XMLSchema#string

J R Kim

http://www.w3.org/2001/XMLSchema#string

J S Ahn

http://www.w3.org/2001/XMLSchema#string

K Park

http://www.w3.org/2001/XMLSchema#string

M J Ahn

http://www.w3.org/2001/XMLSchema#string

S Y Lee

http://www.w3.org/2001/XMLSchema#string

Y L Choi

http://www.w3.org/2001/XMLSchema#string

P2860

The TOR pathway: a target for cancer therapy

Efficacy of everolimus in advanced renal cell carcinoma: a double-blind, randomised, placebo-controlled phase III trial

Everolimus in postmenopausal hormone-receptor-positive advanced breast cancer

Inhibition of the mammalian target of rapamycin (mTOR) by rapamycin increases chemosensitivity of CaSki cells to paclitaxel.

Identifying optimal biologic doses of everolimus (RAD001) in patients with cancer based on the modeling of preclinical and clinical pharmacokinetic and pharmacodynamic data.

Randomized phase III trial comparing irinotecan/cisplatin with etoposide/cisplatin in patients with previously untreated extensive-stage disease small-cell lung cancer.

Safety and pharmacokinetics of paclitaxel and the oral mTOR inhibitor everolimus in advanced solid tumours.

Phase II study of everolimus (RAD001) in previously treated small cell lung cancer.

The combination of RAD001 and NVP-BEZ235 exerts synergistic anticancer activity against non-small cell lung cancer in vitro and in vivo

Phase I pharmacokinetic and pharmacodynamic study of the oral mammalian target of rapamycin inhibitor everolimus in patients with advanced solid tumors.

P2888

P304

1482-1487

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1038/BJC.2013.467

http://www.w3.org/2001/XMLSchema#string

P407

P433

6

http://www.w3.org/2001/XMLSchema#string

P478

109

http://www.w3.org/2001/XMLSchema#string

P577

2013-08-20T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

256074201

http://www.w3.org/2001/XMLSchema#string

P6179

1013308985

http://www.w3.org/2001/XMLSchema#string

P698

23963141

http://www.w3.org/2001/XMLSchema#string

P932

3776982

http://www.w3.org/2001/XMLSchema#string